HIMS Quote, Financials, Valuation and Earnings

Moderna, Inc. has a net margin of 2.63% compared to Hims & Hers Health, Inc.'s net margin of -19.69%. Hims & Hers Health, Inc.'s return on equity of 25.63% beat Moderna, Inc.'s return on equity of -30.18%.

Hims & Hers Health, Inc. has a consensus price target of $46.67, signalling upside risk potential of 26.19%. On the other hand Moderna, Inc. has an analysts' consensus of $39.15 which suggests that it could grow by 58.05%. Given that Moderna, Inc. has higher upside potential than Hims & Hers Health, Inc., analysts believe Moderna, Inc. is more attractive than Hims & Hers Health, Inc..

Hims & Hers Health, Inc. has a beta of 2.200, which suggesting that the stock is 119.991% more volatile than S&P 500. In comparison Moderna, Inc. has a beta of 2.017, suggesting its more volatile than the S&P 500 by 101.68%.

Hims & Hers Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hims & Hers Health, Inc. pays -- of its earnings as a dividend. Moderna, Inc. pays out -- of its earnings as a dividend.

Hims & Hers Health, Inc. quarterly revenues are $599M, which are smaller than Moderna, Inc. quarterly revenues of $1B. Hims & Hers Health, Inc.'s net income of $15.8M is higher than Moderna, Inc.'s net income of -$200M. Notably, Hims & Hers Health, Inc.'s price-to-earnings ratio is 68.37x while Moderna, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hims & Hers Health, Inc. is 4.15x versus 4.30x for Moderna, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of 2.63% compared to Hims & Hers Health, Inc.'s net margin of 21.32%. Hims & Hers Health, Inc.'s return on equity of 25.63% beat Pfizer Inc.'s return on equity of 10.84%.

Hims & Hers Health, Inc. has a consensus price target of $46.67, signalling upside risk potential of 26.19%. On the other hand Pfizer Inc. has an analysts' consensus of $28.96 which suggests that it could grow by 16.05%. Given that Hims & Hers Health, Inc. has higher upside potential than Pfizer Inc., analysts believe Hims & Hers Health, Inc. is more attractive than Pfizer Inc..

Hims & Hers Health, Inc. has a beta of 2.200, which suggesting that the stock is 119.991% more volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.548, suggesting its less volatile than the S&P 500 by 45.194%.

Hims & Hers Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.86% to investors and pays a quarterly dividend of $0.43 per share. Hims & Hers Health, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.

Hims & Hers Health, Inc. quarterly revenues are $599M, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. Hims & Hers Health, Inc.'s net income of $15.8M is lower than Pfizer Inc.'s net income of $3.6B. Notably, Hims & Hers Health, Inc.'s price-to-earnings ratio is 68.37x while Pfizer Inc.'s PE ratio is 14.61x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hims & Hers Health, Inc. is 4.15x versus 2.28x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Recursion Pharmaceuticals, Inc. has a net margin of 2.63% compared to Hims & Hers Health, Inc.'s net margin of -3135.32%. Hims & Hers Health, Inc.'s return on equity of 25.63% beat Recursion Pharmaceuticals, Inc.'s return on equity of -80.23%.

Hims & Hers Health, Inc. has a consensus price target of $46.67, signalling upside risk potential of 26.19%. On the other hand Recursion Pharmaceuticals, Inc. has an analysts' consensus of $6.33 which suggests that it could grow by 52.17%. Given that Recursion Pharmaceuticals, Inc. has higher upside potential than Hims & Hers Health, Inc., analysts believe Recursion Pharmaceuticals, Inc. is more attractive than Hims & Hers Health, Inc..

Hims & Hers Health, Inc. has a beta of 2.200, which suggesting that the stock is 119.991% more volatile than S&P 500. In comparison Recursion Pharmaceuticals, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Hims & Hers Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Recursion Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hims & Hers Health, Inc. pays -- of its earnings as a dividend. Recursion Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Hims & Hers Health, Inc. quarterly revenues are $599M, which are larger than Recursion Pharmaceuticals, Inc. quarterly revenues of $5.2M. Hims & Hers Health, Inc.'s net income of $15.8M is higher than Recursion Pharmaceuticals, Inc.'s net income of -$162.3M. Notably, Hims & Hers Health, Inc.'s price-to-earnings ratio is 68.37x while Recursion Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hims & Hers Health, Inc. is 4.15x versus 37.98x for Recursion Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

UnitedHealth Group, Inc. has a net margin of 2.63% compared to Hims & Hers Health, Inc.'s net margin of 2.25%. Hims & Hers Health, Inc.'s return on equity of 25.63% beat UnitedHealth Group, Inc.'s return on equity of 17.57%.

Hims & Hers Health, Inc. has a consensus price target of $46.67, signalling upside risk potential of 26.19%. On the other hand UnitedHealth Group, Inc. has an analysts' consensus of $385.40 which suggests that it could grow by 19.74%. Given that Hims & Hers Health, Inc. has higher upside potential than UnitedHealth Group, Inc., analysts believe Hims & Hers Health, Inc. is more attractive than UnitedHealth Group, Inc..

Hims & Hers Health, Inc. has a beta of 2.200, which suggesting that the stock is 119.991% more volatile than S&P 500. In comparison UnitedHealth Group, Inc. has a beta of 0.468, suggesting its less volatile than the S&P 500 by 53.175%.

Hims & Hers Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. UnitedHealth Group, Inc. offers a yield of 2.68% to investors and pays a quarterly dividend of $2.21 per share. Hims & Hers Health, Inc. pays -- of its earnings as a dividend. UnitedHealth Group, Inc. pays out 52.75% of its earnings as a dividend. UnitedHealth Group, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Hims & Hers Health, Inc. quarterly revenues are $599M, which are smaller than UnitedHealth Group, Inc. quarterly revenues of $113.2B. Hims & Hers Health, Inc.'s net income of $15.8M is lower than UnitedHealth Group, Inc.'s net income of $2.5B. Notably, Hims & Hers Health, Inc.'s price-to-earnings ratio is 68.37x while UnitedHealth Group, Inc.'s PE ratio is 16.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hims & Hers Health, Inc. is 4.15x versus 0.68x for UnitedHealth Group, Inc.. Usually stocks with elevated PS ratios are considered overvalued.